Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-23 | Gail J. Maderis, M.B.A. has served as President and CEO of Antiva Biosciences, a venture funded biopharma company developing topical therapies to treat the pre-cancerous lesions caused by HPV, since 2015. ... She serves on the corporate boards of Allarity Therapeutics and Valitor, Inc., as well as on the non-profit boards of BIO (Emerging Company and Health Sections), CLSI, The Termeer Foundation and the University of California Berkeley Foundation Board of Trustees. |
| 2022-04-25 | Gail J. Maderis, M.B.A. has served on our Board of Directors since January 2021. ... Ms. Maderis has served as Chairman of the Committee since June 2021. ... At the end of the last fiscal year, the Compensation Committee was composed of Mohammad Azab, David R. Hoffmann and Gail J. Maderis. ... At the end of the last fiscal year, the Audit Committee was composed of the following directors: Simon X. Benito, Peter S. Garcia, David R. Hoffmann, Gail J. Maderis and Judy J. Robertson. |
| 2023-04-27 | Gail J. Maderis, M.B.A. has served on our Board of Directors since January 2021 and as Chair of our Board of Directors since March 2023. ... At the end of the last fiscal year, the Compensation Committee was composed of Mohammad Azab, Peter S. Garcia, David R. Hoffmann and Gail J. Maderis. ... At the end of the last fiscal year, the Audit Committee was composed of the following directors: Peter S. Garcia, David R. Hoffmann, Gail J. Maderis and Judy J. Robertson. ... Director Compensation for Fiscal 2022: Gail J. Maderis, M.B.A. Fees Earned or Paid in Cash ($) 63,000, Option Awards ($) 23,150, Total ($) 86,150. |
| 2024-08-12 | Gail J. Maderis, M.B.A. has served on our Board of Directors since January 2021 and as Chair of our Board of Directors since March 2023. Ms. Maderis has served as Chair of the board of Antiva Biosciences, Inc. since April 2023. Ms. Maderis’ operational, industry and leadership experience in the biopharmaceutical industry as Chief Executive Officer of Five Prime Therapeutics, Inc., Founder and President of Genzyme Molecular Oncology and her current position at Antiva, and her insight into business and policy trends impacting the biopharma industry are among the qualifications she brings to our Board of Directors. Director Compensation for Fiscal 2023 shows cash fees of $86,629 and option awards valued at $23,115, totaling $109,744. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22